Sanofi SA

NASDAQ:SNYUnited States

Today

Show headlines and story abstract

• Regeneron, Sanofi Receive US FDA's Approval for Dupixent as Chronic Obstructive Pulmonary Disease Treatment, from 1 hour ago by MT Newswires

  1 hour ago by MT Newswires
  Companies Mentioned: REGN, SNY
  10:34 AM EDT, 09/27/2024 (MT Newswires) -- Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Friday that Dupixent, or dupilumab, has received approval from the US Food and Drug Administration for treating chronic obstructive pulmonary disease. ...

• DJ Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD, from 1 hour ago by Dow Jones

  1 hour ago by Dow Jones
  Companies Mentioned: REGN, SNY
  
  By Colin Kellaher
  
  Regeneron Pharmaceuticals and Sanofi have won U.S. Food and Drug Administration expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
  

• Dupixent(R) (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD, from 2 hours ago by Dow Jones

  2 hours ago by Dow Jones
  Companies Mentioned: REGN, SNY
  
  government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
  

• Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD, from 2 hours ago by Dow Jones

  2 hours ago by Dow Jones
  Companies Mentioned: SNY
  
  Regeneron's Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA(R) (aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2023 and its Form 10-Q for the quarterly period ended June 30, 2024. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
  

• Sanofi, Regeneron Pharmaceuticals Receive Chinese Regulator's Approval for Dupixent as Chronic Obstructive Pulmonary Disease Treatment, from 4 hours ago by MT Newswires

  4 hours ago by MT Newswires
  Companies Mentioned: REGN, SNY
  07:38 AM EDT, 09/27/2024 (MT Newswires) -- Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) said Friday that China's National Medical Products Administration has approved Dupixent as an add-on maintenance treatment for adults with uncontrolled chro...